Paxlovid for Eligible Patients May Protect You from Prolonged COVID Development

antiviral drug pax robid It was associated with a 26% lower risk of developing long-term COVID. new research Discovered this month. The study concluded that for every 100 people who received antiviral treatment, there were approximately 2.3 fewer cases of long-term COVID detected 90 days after the initial COVID infection.

Paxlovid has been reported to be effective in reducing hospitalizations and deaths after COVID-infection, including those at high risk of developing severe illness from COVID-infection. The study looked at people with at least one potential risk of developing a serious illness, such as being overweight, current smokers, and heart disease or diabetes. The study further found that the drug was associated with a 48% lower risk of death and a 30% lower risk of hospitalization after the first infection. Little is known about the potential effects of this drug on his COVID development in the long term, but a study funded by the U.S. Department of Veterans Affairs (not peer-reviewed) found that early post-infection I have found it to have long term benefits when taken in stages. and 5 days later.

“We are starting to realize that there is a possibility that we could possibly reduce the risk of COVID over the long term,” said study co-author Ziyad Al-Aly, director of research and development at VA Saint Louis Health Care System. says Mr. luck“This is a ray of hope,” he added, adding that for those at high risk, antiviral drugs may offer some protection against the development of long-term COVID-related symptoms.

The study found consistent results regardless of people’s vaccination status, risk level, and whether they had previously had COVID-19. Some people are hesitant to take medication due to reports of rebound infection, but test positive for COVID or develop symptoms after initial recovery.

“Pushing into a winter wave that could affect a lot of people, and those who already qualify for Paxlovid…I think the evidence needs to be weighed,” he says. reduces the risk of acute problems and potentially reduces the risk of long-term complications.”

More than 56,000 participants who were infected with COVID-19 between March and June of this year and had at least one potential risk factor for developing severe illness were studied. 9,217 patients took her 5-day course of Paxlovid within 5 days after initial infection, and 47,123 patients did not take any COVID medication during his first 30 days after infection. did.

Researchers specifically defined at least 1 of 12 post-COVID symptoms 90 days after infection, including shortness of breath, fatigue, muscle pain, ischemic heart disease, arrhythmia, deep vein thrombosis, and pulmonary embolism. was monitored for long-term COVID-19 development, liver disease, acute kidney injury, diabetes, neurocognitive impairment, and cough.

All but two symptoms, cough and new-onset diabetes, were significantly associated with paxlovid. Al-Aly doesn’t know why these two in particular didn’t seem to be related to this drug, but the different post-COVID symptoms are caused by different mechanisms that react with the drug in different ways. I am hypothesizing that it will.

Scientists describe the long COVID as follows: chronic fatigue syndrome, impacting the daily lives of millions of Americans.The Brookings Institution has up to 4 million Americans We are losing our workforce due to the prolonged COVID. The study focused on older Americans, mostly older white men, with at least one underlying medical condition, and Al-Aly said there was still a reduction in risk across various subgroups. , it is important to understand young people post-COVID. people and diverse groups.

“Evaluating paxlovid and low-risk individuals, young people without medical problems, whether it reduces long-term risk of COVID becomes an urgent priority and needs to be addressed,” says Al-Aly .

It is recommended to take the medicine within 5 days after a positive reaction.

sign up for Features of Fortune Subscribe to our mailing list and never miss our biggest features, exclusive interviews and surveys.